The drugmakers plan to start a clinical trial in April testing the freeze-dried vaccine in 1,100 adults ages 18 to 55 in the U.S. The trial is scheduled to last about two months, and if successful, the freeze-dried version could be ready for use by early next year, the Journal reported.
Freeze-dried vaccines only require standard refrigeration. Existing freeze-dried vaccines include those used for shingles and rotavirus, according to the Journal.
Read the full article here.
More articles on pharmacy:
Pfizer, BioNTech to boost COVID-19 vaccine manufacturing to 2.5B doses
GSK to produce Novavax COVID-19 vaccine
Pfizer says its vaccine is 100% effective in preventing COVID-19 in adolescents
